Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOK) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 26,000 shares, a drop of 72.3% from the September 30th total of 93,900 shares. Based on an average daily volume of 72,900 shares, the short-interest ratio is presently 0.4 days. Currently, 3.5% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Evoke Pharma in a report on Saturday, October 19th. They issued a “sell” rating for the company.

Evoke Pharma Stock Performance

NASDAQ EVOK traded up $0.17 during mid-day trading on Friday, reaching $5.30. 13,825 shares of the stock were exchanged, compared to its average volume of 25,366. Evoke Pharma has a 1 year low of $3.54 and a 1 year high of $17.88. The business’s 50 day moving average is $4.77 and its 200-day moving average is $5.52. The company has a market capitalization of $45.56 million, a P/E ratio of -2.90 and a beta of 0.39.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). The business had revenue of $2.55 million during the quarter. Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.